Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 4, 2013-11 ,pp. : 200-201

Karger

Access to resources Recommend Favorite

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 15-16

Karger

Access to resources Recommend Favorite

Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 118, Iss. 1, 2007-03 ,pp. : 7-9

Karger

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg^®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite